Therapy News and Research

RSS

Lilly, Boehringer Ingelheim receive positive opinion from EMA for Jentadueto

Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a positive opinion from the European Medicines Agency's medicinal committee recommending approval of Jentadueto,which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes who need to improve control of their blood glucose.

28 May 2012

Overactive BAALC gene found in people with acute leukemia

A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.

25 May 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012

Gene therapy can effectively treat ADA-deficient severe combined immunodeficiency

Severe combined immunodeficiency is defect in the immune system that results in a loss of the adaptive immune cells known as B cells and T cells. Mutations in several different genes can lead to the development of severe combined immunodeficiency, including mutation of the adenosine deaminase (ADA) gene. Traditional treatment options, such as enzyme replacement therapy, are of limited efficacy, but bone marrow transplant from a compatible donor leads to a better response.

25 May 2012

Researchers uncover series of biological events that implicate stem cells' surroundings

Stem cells are essential building blocks for all organisms, from plants to humans. They can divide and renew themselves throughout life, differentiating into the specialized tissues needed during development, as well as cells necessary to repair adult tissue.

25 May 2012

New treatment model of psychotherapy now listed on SAMHSA's national registry

A new treatment model of psychodynamic psychotherapy pioneered at Upstate Medical University for symptoms of borderline personality disorder, depression, heavy drinking, suicide attempts and self-harm behaviors is now listed on the Substance Abuse and Mental Health Services Administration (SAMHSA) National Registry of Evidence-based Practices and Programs.

25 May 2012

Ministers meet to discuss Global Plan to eliminate new HIV infections among children

UNAIDS and PEPFAR recently brought together the ministers of health and representatives of the 22 countries with the most new HIV cases among children to discuss progress on the Global Plan towards the Elimination of New HIV Infections among Children by 2015 and Keeping Their Mothers Alive, agreed to at the 2011 U.N. High-Level Meeting on AIDS, according to a UNAIDS press release.

25 May 2012

UCSF scientists aim to use embryonic stem cells for treatment of neuropathic pain

Chronic pain, by definition, is difficult to manage, but a new study by UCSF scientists shows how a cell therapy might one day be used not only to quell some common types of persistent and difficult-to-treat pain, but also to cure the conditions that give rise to them.

25 May 2012

New compound can enhance apoptosis in cancer cells

The BCL-2 protein family plays a large role in determining whether cancer cells survive in response to therapy or undergo a form of cell death known as apoptosis.

25 May 2012

FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

Pfizer Inc. announced today that the United States Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted on Pfizer's clinical data package for tafamidis meglumine.

25 May 2012

UofL receives Helmsley Charitable Trust grant to develop technology for paralyzed people

The University of Louisville has received $6.3 million from the Leona M. and Harry B. Helmsley Charitable Trust to support research in the Department of Neurological Surgery and the Kentucky Spinal Cord Injury Research Center at UofL developing the next generation of technology to help paralyzed people regain movement in their limbs and enhance their quality of life.

25 May 2012

WSU introduces web-based decision support system to select wheeled mobility devices

A Wayne State University researcher has introduced computer technology that makes it easier for people who need wheelchairs to select one that best suits their needs.

25 May 2012

Scars, disfigurement and hair loss from childhood cancer can affect adult quality of life

Scars left behind by childhood cancer treatments are more than skin-deep. The increased risk of disfigurement and persistent hair loss caused by childhood cancer and treatment are associated with emotional distress and reduced quality of life in adulthood, according to a new study led by a Northwestern Medicine advanced practice nurse, Karen Kinahan, and based on data from the Childhood Cancer Survivor Study.

25 May 2012

Poor cardio-pulmonary function may be strong predictor of survival in women with breast cancer

Women receiving care for breast cancer have significantly impaired cardio-pulmonary function that can persist for years after they have completed treatment, according to a study led by scientists at Duke University Medical Center.

25 May 2012

Auxilium, FCB I file suit against Watson over generic Testim

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim 1%.

25 May 2012

LVRC safe and effective choice for patients with severe heterogeneous emphysema

A tiny, resilient metal wire designed to gather and compress diseased lung tissue may offer relief to patients with severe heterogeneous emphysema, a subtype of the disease that involves specific, usually isolated areas of the lungs, according to the results of a multicenter international trial conducted in the Netherlands, Germany and France. The wire, called a lung volume reduction coil (LVRC), can be easily implanted and is designed to take the place of more invasive procedures used to improve the lung function of emphysema patients.

24 May 2012

Positive Results for Pulsar Stent in Clinical Study – BIOTRONIK announces

The six-month results from the prospective, multicenter, single-arm 4EVER study demonstrate efficacy and safety of BIOTRONIK's Pulsar Stent System in 120 superficial femoral artery (SFA) patients. Analysis of the 120 patients showed excellent device performance, very promising patency rates and convincing evidence of the benefits of lower limb intervention on a 4F platform. Although only the interim results were presented at the Leipzig Interventional Course (LINC 2012) in Leipzig, Germany, analysis of the full cohort has recently been made available.

24 May 2012

Optogenetic Therapies for Vision workshop to be held on June 1

The Foundation Fighting Blindness and Massachusetts Eye and Ear will host the Optogenetic Therapies for Vision workshop on Friday, June 1, from 8 a.m.-6 p.m., in Boston.

24 May 2012

Optimi prototype effectively predicts people at risk of depression

The computing tool, developed by researchers at the Universitat Jaume I in Castellón, the Universitat Politècnica of València and the Universitat de València, along with professionals from the company everis, is able to predict if a person with a high-stress level is at risk of becoming depressed, based on the study of a series of physiological and psychological variables in which artificial intelligence techniques are used.

24 May 2012

Tenn. doctors, Blue Cross and Blue Shield agree to bundle payments for knee, hip replacements

In other insurance company news, BlueCross Blue Shield of Illinois will pay $25M to settle coverage denial claims.

24 May 2012

Therapy News and Research

Lilly, Boehringer Ingelheim receive positive opinion from EMA for Jentadueto

Overactive BAALC gene found in people with acute leukemia

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Gene therapy can effectively treat ADA-deficient severe combined immunodeficiency

Researchers uncover series of biological events that implicate stem cells' surroundings

New treatment model of psychotherapy now listed on SAMHSA's national registry

Ministers meet to discuss Global Plan to eliminate new HIV infections among children

UCSF scientists aim to use embryonic stem cells for treatment of neuropathic pain

New compound can enhance apoptosis in cancer cells

FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

UofL receives Helmsley Charitable Trust grant to develop technology for paralyzed people

WSU introduces web-based decision support system to select wheeled mobility devices

Scars, disfigurement and hair loss from childhood cancer can affect adult quality of life

Poor cardio-pulmonary function may be strong predictor of survival in women with breast cancer

Auxilium, FCB I file suit against Watson over generic Testim

LVRC safe and effective choice for patients with severe heterogeneous emphysema

Positive Results for Pulsar Stent in Clinical Study – BIOTRONIK announces

Optogenetic Therapies for Vision workshop to be held on June 1

Optimi prototype effectively predicts people at risk of depression

Tenn. doctors, Blue Cross and Blue Shield agree to bundle payments for knee, hip replacements

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News